Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Schoretsanitis G, de Leon J, Eap CB, Kane JM, Paulzen M.

CNS Drugs. 2019 Dec;33(12):1201-1222. doi: 10.1007/s40263-019-00683-7. Review.

PMID:
31776871
2.

The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism.

Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Gründer G, Paulzen M.

Pharmacopsychiatry. 2019 Oct 15. doi: 10.1055/a-1021-8827. [Epub ahead of print]

PMID:
31614374
3.

Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: A systematic critical review and combined analysis.

Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M.

Ther Drug Monit. 2019 Aug 16. doi: 10.1097/FTD.0000000000000692. [Epub ahead of print]

PMID:
31425493
4.

[Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].

Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C.

Nervenarzt. 2019 Sep;90(9):958-960. doi: 10.1007/s00115-019-0766-7. German. No abstract available.

PMID:
31309271
5.

Inferior frontal gyrus gray matter volume is associated with aggressive behavior in schizophrenia spectrum disorders.

Schoretsanitis G, Stegmayer K, Razavi N, Federspiel A, Müller TJ, Horn H, Wiest R, Strik W, Walther S.

Psychiatry Res Neuroimaging. 2019 Aug 30;290:14-21. doi: 10.1016/j.pscychresns.2019.06.003. Epub 2019 Jun 22.

PMID:
31254799
6.

Gemfibrozil May Decrease Norclozapine Elimination: A Case Report.

Barclay J, McCollum B, Schoretsanitis G, de Leon J.

J Clin Psychopharmacol. 2019 Jul/Aug;39(4):405-407. doi: 10.1097/JCP.0000000000001050. No abstract available.

PMID:
31205191
7.

Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.

Augustin M, Schoretsanitis G, Pfeifer P, Gründer G, Liebe C, Paulzen M.

Schizophr Res. 2019 Aug;210:143-148. doi: 10.1016/j.schres.2019.05.033. Epub 2019 Jun 8.

PMID:
31182321
8.

Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.

Kowalewski C, Haen E, Hiemke C, Ridders F, Endres K, Gründer G, Paulzen M, Schoretsanitis G.

Int Clin Psychopharmacol. 2019 Sep;34(5):241-246. doi: 10.1097/YIC.0000000000000268.

PMID:
31094902
9.

A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients.

Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):603-621. doi: 10.1080/17512433.2019.1617695. Epub 2019 May 31.

PMID:
31075044
10.

Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database.

Schoretsanitis G, Haen E, Gründer G, Hiemke C, Endres K, Ridders F, Correll CU, Paulzen M.

Eur J Clin Pharmacol. 2019 Aug;75(8):1109-1116. doi: 10.1007/s00228-019-02675-4. Epub 2019 Apr 9.

PMID:
30968172
11.

Pharmacokinetic correlates of venlafaxine: associated adverse reactions.

Schoretsanitis G, Haen E, Hiemke C, Endres K, Ridders F, Veselinovic T, Gründer G, Paulzen M.

Eur Arch Psychiatry Clin Neurosci. 2019 Oct;269(7):851-857. doi: 10.1007/s00406-019-01005-0. Epub 2019 Mar 28.

PMID:
30923938
12.

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone.

Schoretsanitis G, Spina E, Hiemke C, de Leon J.

Expert Rev Clin Pharmacol. 2018 Dec;11(12):1237-1253. doi: 10.1080/17512433.2018.1549489. Epub 2018 Dec 4.

PMID:
30449206
13.

[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].

Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C.

Nervenarzt. 2019 May;90(5):463-471. doi: 10.1007/s00115-018-0643-9. Review. German. Erratum in: Nervenarzt. 2019 Jul 15;:.

PMID:
30446893
14.

Studies of Half-Lives of Long-Acting Antipsychotics are Needed.

Schoretsanitis G, Villasante-Tezanos AG, de Leon J.

Pharmacopsychiatry. 2019 Jan;52(1):45-46. doi: 10.1055/a-0755-7692. Epub 2018 Oct 22.

PMID:
30347421
15.

Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine.

Paulzen M, Stingl JC, Augustin M, Saßmannshausen H, Franz C, Gründer G, Schoretsanitis G.

Clin Pharmacokinet. 2019 Apr;58(4):535-543. doi: 10.1007/s40262-018-0713-y.

PMID:
30255309
16.

Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism.

Augustin M, Schoretsanitis G, Hiemke C, Gründer G, Haen E, Paulzen M.

J Clin Psychiatry. 2018 Sep 4;79(5). pii: 17m12086. doi: 10.4088/JCP.17m12086.

PMID:
30192450
17.

Antidepressants in breast milk; comparative analysis of excretion ratios.

Schoretsanitis G, Augustin M, Saßmannshausen H, Franz C, Gründer G, Paulzen M.

Arch Womens Ment Health. 2019 Jun;22(3):383-390. doi: 10.1007/s00737-018-0905-3. Epub 2018 Aug 16.

PMID:
30116895
18.

How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.

Augustin M, Schoretsanitis G, Gründer G, Haen E, Paulzen M.

J Clin Psychopharmacol. 2018 Oct;38(5):498-501. doi: 10.1097/JCP.0000000000000929.

PMID:
30102628
19.

Sex and body weight are major determinants of venlafaxine pharmacokinetics.

Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Gründer G, Paulzen M.

Int Clin Psychopharmacol. 2018 Nov;33(6):322-329. doi: 10.1097/YIC.0000000000000234.

PMID:
30028351
20.

Upon Rejection: Psychiatric Emergencies of Failed Asylum Seekers.

Schoretsanitis G, Bhugra D, Eisenhardt S, Ricklin ME, Srivastava DS, Exadaktylos A, Walther S.

Int J Environ Res Public Health. 2018 Jul 16;15(7). pii: E1498. doi: 10.3390/ijerph15071498.

Supplemental Content

Loading ...
Support Center